Inspiratory muscle training for people with inflammatory myopathy
Official title: The Effect of Inspiratory Muscle Training on the Functional Status of Patients With Inflammatory Myopathy
Run by Józef Piłsudski University of Physical Education · NCT07274267 · Data updated 2026-11-12
This project will test whether a 3-month home-based inspiratory muscle training program can strengthen breathing muscles and improve walking distance, fatigue, and quality of life for adults with inflammatory myopathy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 33 (estimated) |
| Sponsor | Józef Piłsudski University of Physical Education Academic / other |
| Locations | 1 site (Warsaw) |
| Status | Recruiting |
| Started | August 12, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | February 25, 2026 |
| Trial ID | NCT07274267 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with a confirmed diagnosis of inflammatory myopathy who are clinically stable, able to perform and follow a home exercise program, and able to give informed consent are ideal candidates.
✕Probably not a fit
Patients with active respiratory infection, recent respiratory muscle training, history of spontaneous pneumothorax, pulmonary hypertension, certain ear pathologies, cognitive impairment, or inability to follow the program may not receive benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot interventional program enrolls 33 adults with inflammatory myopathy to complete a 3-month home-based inspiratory muscle training (IMT) regimen using a Threshold IMT device, with daily sessions of 30 breaths and progressive resistance starting at 30% of maximal inspiratory pressure. Participants receive individualized instruction, biweekly phone follow-up, and record adherence in exercise diaries. Outcomes measured at baseline and follow-up include inspiratory muscle strength, spirometry, diaphragm ultrasound, six-minute walk distance, fatigue scales, and quality-of-life questionnaires. The study aims to link improvements in inspiratory muscle strength to better functional performance and patient-reported outcomes.
Why it matters
Potential benefit: If successful, IMT could increase inspiratory muscle strength, reduce breathlessness and fatigue, and improve exercise tolerance and quality of life for people with inflammatory myopathy.
How similar studies have gone: Inspiratory muscle training has shown benefits in other neuromuscular and respiratory conditions, but direct evidence in inflammatory myopathy is limited and this application is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of inflammatory myopathy according to European Alliance of Associations for Rheumatology / American College of Rheumatology criteria * Age ≥ 18 years * Stable clinical condition allowing participation in physical activity * Ability to understand and follow instructions * Written informed consent to participate in the study Exclusion Criteria: * Cognitive impairment preventing proper exercise performance * Current respiratory tract infection * Previous respiratory muscle training within the last 12 months * History of spontaneous pneumothorax * Pulmonary hypertension * Tympanic membrane rupture or other middle ear pathology * Lack of voluntary and informed consent
Where it's running
-
University Clinical Center of the Medical University of Warsaw
Warsaw, Poland Recruiting
Study contacts
- Study coordinator: Jan Sznajder, PhD
- Email: jan.sznajder@awf.edu.pl
- Phone: +48696994812
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Interferon patterns in cancer patients receiving CTLA-4 or PD-1/PD-L1 inhibitors versus autoimmune disease
This project will test whether blood interferon levels can help predict immune-related side effects in adults starting checkpoint inhibitor immunotherapy by comparing them with people who have autoimmune diseases.
-
Universal CD19-targeting CAR-γδT cell therapy for refractory autoimmune diseases
This trial will try infusing universal CD19-targeting CAR-γδT cells into adults with refractory B cell–driven autoimmune diseases to see if removing autoreactive B cells improves symptoms.
-
Identifying biomarkers in systemic sclerosis and inflammatory myopathies
This study is trying to find specific markers in the blood and tissues of people with systemic sclerosis and inflammatory myopathies to better understand their diseases and how they progress over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.